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1998 alone. The 5-year survival for non–small cell lung
cancer remains 14% despite recent advancements in
chemotherapy and radiotherapy. Paclitaxel (Taxol) is an
antineoplastic agent that has shown promise in the treat-
ment of non–small cell lung cancer. Paclitaxel prevents
microtubule disaggregation and induces tumor cell
death by apoptosis. Paclitaxel-treated tumor cells arrest
in the G2-M phase of the cell cycle, leading to apoptot-
ic cell death.1 Apoptosis is a morphologically distinct
form of programmed cell death that is associated with
chromatin condensation, cytoskeletal alterations, and
membrane blebbing. Mitochondrial function is irre-
versibly impaired early in apoptosis.2 In a later stage of
apoptosis, nuclear fragmentation becomes evident
(karyorrhexis), the cytoplasm condenses progressively,
and one or more apoptotic bodies are formed from each
dying cell. The events occurring between the stabiliza-
tion of microtubules and the initiation of apoptosis are
unclear, but downstream intracellular events include
cleavage of DNA3 and activation of several caspases.4
At least 14 separate caspases have been identified and
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Objective: Our objective was to determine whether paclitaxel-induced apop-
tosis in human lung cancer cells is Fas dependent.
Methods: Human lung cancer cell lines were evaluated for morphologic evi-
dence of apoptosis, DNA fragmentation (TUNEL positivity), and caspase-3
activation after paclitaxel treatment. Human lung adenocarcinoma, squa-
mous cell carcinoma, undifferentiated lung carcinoma, and bronchoalveolar
carcinoma cell lines were each cultured in 10 µmol/L paclitaxel.
Results: After 24 hours of culture in paclitaxel, a 22% to 69% increase in the
number of apoptotic cells was evident by means of methylene blue-azure A-
eosin staining with characteristic blebbing and nuclear condensation.
TUNEL assay also confirmed an increase of 19.9% to 73.0% of cells with
nuclear fragmentation. Caspase-3 activity, assayed by Z-DEVD cleavage,
increased from 20% to 215% (P < .05). ZB4, an antagonistic anti-Fas anti-
body, did not block paclitaxel induction of caspase-3 activity (155.8 vs 165.8
U, not significant). Apoptotic morphologic changes were inhibited in cells
cultured in the presence of paclitaxel and Ac-DEVD-CHO, a caspase-3
inhibitor.
Conclusions: Paclitaxel induces apoptosis in lung cancer cell lines, as
assessed by a consistent increase in caspase-3 activity, DNA laddering, and
characteristic morphologic changes. Paclitaxel-induced apoptosis in human
lung cancer cells is associated with caspase-3 activation but is not Fas depen-
dent. (J Thorac Cardiovasc Surg 2000;119:795-803)
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form a multigene family containing 4 distinct domains:
an amino-terminal domain, a large subunit, a small sub-
unit, and a linker region between the large and small
subunits. Activation of each caspase is induced by pro-
teolytic cleavage between domains.5 Mammalian cell
death proteases have been divided into upstream (ini-
tiator) and downstream (effector) caspases on the basis
of their sites of action in the proteolytic caspase cas-
cade. Initiator caspases have long prodomains, and effec-
tor caspases have characteristic short prodomains.
Caspase-3 (CPP32), an effector caspase, is a key member
of the caspase family. Poly (ADP-ribose) polymerase, an
enzyme involved in DNA repair, is cleaved during apop-
tosis3 and serves as a substrate for caspase-3.6
Several anticancer drugs applied in the treatment of
lung cancer, including bleomycin, doxorobucin, etopo-
side (VP-16), cisplatin, and methotrexate, have been
reported to enhance Fas ligand (FasL) expression on
the surface of Fas receptor–expressing cells, suggesting
that apoptosis caused by these drugs may be mediated
by means of Fas cross-linking.7,8 Fas (CD95) is a tumor
necrosis factor (TNF) receptor family member contain-
ing a death effector domain. FasL (CD95L) cross-link-
ing of Fas induces apoptotic cell death in both lym-
phoid and nonlymphoid cells.9 Fas is constitutively
expressed on a variety of normal and tumor cells,10-12
including human lung carcinoma cells.13,14 Down-
stream signaling from the Fas receptor is initiated by
the recruitment of proteins to form a death-inducing
signaling complex.15 Binding of FasL to Fas results in
the recruitment of Fas-associating protein with death
domain, which in turn interacts with the death domain
of the trimerized Fas receptor. Fas-associating protein
with death domain is responsible for the cleavage of the
first of the series of caspases, caspase-8.
Activation of caspase-3 and caspase-9 has been
recently demonstrated in HL-60 leukemia cells after
paclitaxel treatment, with no significant alteration of
HL-60 Fas or FasL expression.16 The mechanism of
paclitaxel-induced lung carcinoma cell death and the
intracellular events associated with paclitaxel treatment
have not been elucidated. We thus studied the apoptot-
ic cell death in paclitaxel-treated lung carcinoma cells,
examining both caspase-3 activity and the role of the
Fas-FasL pathway.
Material and methods
Reagents. The drug paclitaxel was purchased from Sigma
Chemical Company (St Louis, Mo) as a pure substance and
was dissolved and stored in dimethyl sulfoxide before use in
individual experiments. Culture media (Dulbecco’s modified
Eagle’s medium and Roswell Park Memorial Institute medi-
um), fetal bovine serum (FBS), streptomycin, and penicil-
lamine were obtained from Gibco BRL (Grand Island, NY).
The monoclonal agonistic anti-human Fas immunoglobulin
(Ig) M (clone CH11) and the monoclonal anti-human Fas
IgG1 (clone ZB4) were obtained from Upstate Biotechnology
(Lake Placid, NY). The F(ab´)2 fragment of goat anti-mouse
IgG (Fc specific) used as a secondary antibody for clone ZB4
was obtained from Sigma.
Tumor cell lines and cell culture. Human lung carcinoma
cell lines 201T and 84T were previously established from
endobronchial biopsy specimens from patients with lung can-
cer. The 84T cell line was derived from a bronchogenic squa-
mous cell carcinoma and initially cultured in A549-condi-
tioned medium and 1% bovine serum, as was 201T, an
undifferentiated lung carcinoma cell line.17 Both 201T and
84T cells were grown in basal medium Eagle with 100 µg/mL
streptomycin, 100 U/mL penicillin, and 10% FBS. A549,
H226, H596, and H358 cell lines were obtained from the
American Type Tissue Culture Collection (ATCC, Rockville,
Md; ATCC No.: CCL185, CRL-5826, HTB 178, and CRL-
5807, respectively) and are bronchogenic adenocarcinoma,18
squamous cell carcinoma, adenosquamous carcinoma, and
bronchoalveolar carcinoma, respectively. These cell lines
were each cultured in Roswell Park Memorial Institute medi-
um supplemented with 100 µg/mL streptomycin, 100 U/mL
penicillin, and 10% FBS (complete medium) and grown until
80% confluence before paclitaxel treatment.
Morphologic analysis of paclitaxel-treated cells. Cell
morphology was examined by using methylene blue–azure
A–eosin staining of cells with a leukostat stain kit (Fisher,
Pittsburgh, Pa). After a 24-hour incubation period with or
without paclitaxel (10 µmol/L), cells were cytospun, fixed,
and stained with eosin and methylene blue–azure A. Viability,
paclitaxel-induced cytotoxicity, or both were assessed by
means of trypan blue exclusion.
TUNEL on cytospun slides. Cell morphology and apop-
totic cell death can be simultaneously examined by TUNEL
staining (terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling) performed on cytospun slides. DNA
fragmentation, present in apoptotic cells, can be quantitated
by the identification of multiple DNA 3´-hydroxy termini.
This property can be used to identify apoptotic cells by label-
ing the DNA breaks with fluorescein isothiocyanate–tagged
deoxyuridine triphosphate nucleotides. The enzyme terminal
deoxynucleotidyl transferase (TdT) catalyzes template-inde-
pendent addition of deoxyribonucleoside triphosphate to the
3´-hydroxyl ends of double- or single-stranded DNA. Cyto-
spin preparations of lung carcinoma cells were made after 24
hours of incubation with or without paclitaxel (10 µmol/L)
and assessed by means of TUNEL staining with a TdT
FragEL fragmentation detection kit (Oncogene Research
Products, Cambridge, Mass). Briefly, cells were permeabi-
lized with proteinase K (20 µg/mL) and treated with 30%
H2O2 to inactivate endogenous peroxidases. DNA fragments
were then labeled by means of fluorescein isothiocyanate–
tagged deoxyuridine triphosphate nucleotides by using the
TdT enzyme for 1.5 hours at 37°C before termination of the
labeling with 0.5 mol/L ethylenediamine tetraacetic acid (pH
8). A blocking step with 4% bovine serum albumin in phos-
H596, 84T, and 201T) exhibited little apoptosis
(0.7%-5% of cells). The addition of paclitaxel to
tumor cell cultures for 24 hours increased the relative
number of apoptotic cells, as assessed by morpholog-
ic analysis, by 22% to 69% (P < .05; Fig 1). TUNEL
assay confirmed an increase in apoptotic cells of 19%
to 73%, depending on the individual cell line tested (P
< .05; Fig 2).
Paclitaxel increases caspase-3 activity. Caspase-3
activity was assayed by using a Z-DEVD cleavage
assay. Basal caspase-3 activity in controls (untreated
cells) was between 13 and 83 units, depending on the
cell line tested. Culture in paclitaxel for 24 hours
resulted in a significant increase in caspase-3 activity in
A549, H226, H358, H596, and 84T cell lines (P < .05;
range, P = .01-.03). This increase in caspase-3 activity
was reproducible for multiple experiments performed
on 5 of 6 cell lines tested (R = 0.94-0.99; Fig 3).
Paclitaxel-induced apoptosis is reversed by Ac-
DEVD-CHO, a caspase-3 inhibitor. Caspase-3
activity was assayed in 3 different lung cancer cell
lines (A549, H358, and H596) cultured in paclitaxel
for 24 hours in the presence or absence of a caspase-
3 inhibitor (Ac-DEVD-CHO). Induction of caspase-3
activity by paclitaxel in the presence of Ac-DEVD-
CHO was decreased by 10.5% to 786.8% when com-
pared with control cells (paclitaxel alone; Table I).
The addition of Ac-DEVD-CHO also prevented the
characteristic morphologic changes associated with
apoptosis, such as membrane blebbing and nuclear
condensation.
Paclitaxel-induced apoptosis is not blocked by the
anti-Fas antibody ZB4. A549, H226, and H358 cell
lines were cultured for 24 hours in paclitaxel (10
µmol/L) or ZB4 (500 ng/mL), an antagonistic anti-Fas
antibody that blocks the activity of Fas receptor, alone.
In addition, A549, H226, and H358 cell lines were cul-
tured in the presence of both paclitaxel (10 µmol/L)
and ZB4 (500 ng/mL). The addition of ZB4 did not
block paclitaxel induction of caspase-3 activity in these
cell lines (Fig 4). Furthermore, the addition of a sec-
ondary F(ab´)2 fragment, Fc-specific, cross-linking
antibody to ZB4 did not block paclitaxel induction of
caspase-3 activity (data not shown).
Discussion
In the present study we investigated the intracellular
mechanisms involved in paclitaxel-induced apoptosis
in human lung cancer cell lines. We showed that pacli-
taxel induced the characteristic morphologic changes
observed in apoptosis, including membrane blebbing
and nuclear condensation, as well as DNA fragmenta-
tion. Culture in paclitaxel for 24 hours induced a sig-
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phate-buffered saline solution was followed by detection with
peroxidase streptavidin and 3,3´-diaminobenzidine staining.
Slides were counterstained with a methyl green solution and
fixed in 100% ethanol before microscopic examination.
Caspase-3 activity assay. Caspase-3 is a marker for cells
entering apoptosis. Caspase-3 activity can be measured in an
assay on the basis of the cleavage of its substrate, the fluoro-
genic peptide Z-DEVD-AFC (carbobenzoxy-Asp-Glu-Val-
Asp-7-amino-4-trifluoromethyl coumarin; Biorad, Hercules,
Calif). After paclitaxel treatment, cells were trypsinized,
washed, and adjusted to the same number of cells for each
culture condition tested. Pelleted cells were resuspended in
lysis buffer and submitted to 4 freeze-thaw steps before the
addition of the substrate Z-DEVD-AFC. Luminescence was
assessed at time 0 and time 1 hour by fluorometry (lumines-
cence fluorometer Perkin Elmer LS50B; PE Corporation,
Norwalk, Conn). Caspase-3 activity values, calculated from a
standard curve and generated by using varying concentrations
of Z-DEVD-AFC, were expressed in units. Apoptosis was
also assessed in lung cancer cells cultured with paclitaxel (10
µmol/L) in the presence or absence of a caspase-3 inhibitor
(Ac-DEVD-CHO; Pharmingen, San Diego, Calif). Ac-
DEVD-CHO was added to cell cultures 24 hours before
paclitaxel treatment at a concentration of 500 ng/mL.
Treatment of cells with paclitaxel and an anti-Fas anti-
body (ZB4). To determine whether paclitaxel induces apop-
tosis through the activation of the Fas receptor in a function-
al assay, we cultured lung carcinoma cells in the presence of
paclitaxel (10 µmol/L) with and without ZB4 (500 ng/mL),
an anti-Fas antibody that blocks Fas receptor activity.9 ZB4
was added 1 hour before treatment with paclitaxel. Cells were
harvested at 24 hours, and apoptosis was quantified by mea-
surement of caspase-3 activity, as previously described.
Statistical analysis. Data were expressed as means ± SE
and were obtained from an average of 3 to 5 different exper-
iments per cell line. Each experiment included internal con-
trols with the same pool of cells. Derived values were
expressed as a percentage of the respective controls for indi-
vidual experiments. The nonparametric Mann-Whitney U test
was used for comparison to derive P values. A standard lin-
ear regression was used for all correlations (R values).
Calculations and statistical analysis were performed by using
the Statview SE II statistical package (Abacus Concepts,
Berkeley, Calif).
Results
Paclitaxel induces apoptosis in cultured human
lung cancer cells. As evidenced by morphologic and
biochemical assays, paclitaxel (10 µmol/L) induced
apoptotic cell death in human lung cancer cells.
Optimal cytotoxicity occurred 24 hours after paclitax-
el treatment, as detected by trypan blue exclusion
with 10 µmol/L paclitaxel (data not shown). At this
concentration, paclitaxel arrested cells in the G2-M
phase of the cell cycle (data not shown). In the basal
state cultured lung cancer cells (A549, H226, H358,
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Fig 1. Paclitaxel-treated human lung carcinoma cells undergo characteristic changes of apoptotic cell death with
condensation of nuclear chromatin, membrane blebbing, and karyorrhexis. Cells were cultured for 24 hours in the
presence or absence of paclitaxel (10 µmol/L). At the end of the incubation period, cells were harvested and
stained with methylene blue–azure A–eosin dye (magnification ×40). PA, Paclitaxel; A549, lung adenocarcinoma
cells; H358, lung bronchoalveolar carcinoma cells; 201T, undifferentiated lung carcinoma cells; H226, squamous
cell lung carcinoma cells; 84T, squamous cell lung carcinoma; H596, adenosquamous lung carcinoma.
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Fig 2. Paclitaxel-treated lung cancer cell lines demonstrate TUNEL positivity. After 24 hours of culture in pacli-
taxel (10 µmol/L), cells were harvested and assessed for TUNEL positivity (magnification ×10 and ×40). PA,
Paclitaxel; A549, lung adenocarcinoma cells; H358, lung bronchoalveolar carcinoma cells; 201T, undifferentiat-
ed lung carcinoma cells; H226, squamous cell lung carcinoma cells; 84T, squamous cell lung carcinoma; H596,
adenosquamous lung carcinoma.
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Fig 3. Paclitaxel increased caspase-3 activity in all lung cancer cell lines tested. Tumor cells were cultured for 24
hours with or without paclitaxel (10 µmol/L) and were assessed for caspase-3 activity by means of a Z-DEVD-
AFC fluorometric cleavage assay. Each box represents a separate cell line. Experiments were repeated 3 to 5 times
per cell line (as indicated by the individual series shown), with good correlation between experiments (R = 0.94-
0.99 in 5 of 6 cell lines studied). PA, Paclitaxel; A549, lung adenocarcinoma cells; H358, lung bronchoalveolar
carcinoma cells; 201T, undifferentiated lung carcinoma cells; H226, squamous cell lung carcinoma cells; 84T,
squamous cell lung carcinoma; H596, adenosquamous lung carcinoma.
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nificant increase in caspase-3 activity in all lung cancer
cell lines tested. In addition, the addition of an anti-Fas
antagonistic antibody failed to block the induction of
apoptosis by paclitaxel.
Upregulation of Fas and FasL on the surface of tumor
cells after chemotherapy treatment has been demon-
strated.19 Several investigators have reported that drug-
induced apoptosis can involve Fas cross-linking.12,19
Table I. Paclitaxel-induced apoptosis is blocked by a caspase-3 inhibitor
Caspase-3 Paclitaxel + Percentage 
Cell lines Controls inhibitor Paclitaxel caspase-3 inhibitor inhibition*
H358 37.3 33.9 1085.8 298.9 786.84
A549 42.2 30.6 68.3 50.4 42.4
A549 62.1 49.6 69.4 62.9 10.5
H596 19.9 17.8 57.1 24.2 164.3
Cell lines (A549, H358, and H596) were treated for 24 hours with dimethyl sulfoxide (controls); paclitaxel (10 µmol/L); caspase-3 inhibitor (Ac-DEVD-CHO; 500
ng/mL); or paclitaxel (10 µmol/L) plus Ac-DEVD-CHO (500 ng/mL). Caspase-3 activity in cells was assayed by Z-DEVD-AFC cleavage and expressed in units.
*Paclitaxel alone versus paclitaxel plus caspase-3 inhibitor.
Fig 4. Paclitaxel-induced apoptosis is not blocked by the antagonistic anti-FAS antibody ZB4. A, A549, H358,
and H596 cells were cultured in 10 µmol/L paclitaxel for 24 hours in the presence or absence of the antagonistic
anti-FAS antibody (ZB4). Experiments were performed in duplicate for each of the 3 cell lines studied. PA,
Paclitaxel. B, CH11 (agonistic Fas antibody)-induced caspase-3 activity was inhibited by ZB4. Fas-sensitive
Jurkat cells were used as positive controls to test the ability of ZB4 to block caspase-3 activity induced by CH11,
an agonistic FAS antibody. 0, No antibody treatment; A549, lung adenocarcinoma cells; H358, lung bron-
choalveolar carcinoma cells; H226, squamous cell lung carcinoma cells.
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murine lung cancers, including the 3LL tumor, and
potential application in human clinical trials suggest
that coupling chemotherapeutic agents (as a source of
apoptotic bodies) with immunotherapies (dendritic
cells) may be possible. Means to enhance delivery of
dendritic cells to sites of tumor undergoing paclitaxel-
induced apoptotic death then becomes an exciting anti-
tumor strategy. We are in the process of performing
studies in vitro to assess the ability of paclitaxel to pro-
mote apoptotic death of tumor cells capable of being
taken up by dendritic cells and contrasting this with
that of other inducers of apoptosis, including gamma
radiation, ultraviolet irradiation, serum starvation, FasL
or TNF cross-linking, natural killer–induced lysis, and
photodynamic therapy. We hope to use this information
to initiate a new generation of adjuvant and possibly
neoadjuvant strategies in patients with lung cancer.
In conclusion, paclitaxel-induced apoptosis is not
mediated by Fas in the lung cancer cell lines tested.
Caspase-3 activity is significantly increased after cul-
ture in the presence of paclitaxel, and lung cancer cells
demonstrate the characteristic morphologic features of
apoptotic cell death.
We thank Dr Galina Shurin, Chris Matsko, Andreas Albers,
Quan Cai, Kazumasa Hiroishi, Tatsuya Kanto, and Robbie
Mailliard for the expert advice in the elaboration of the exper-
iments, as well as Jill M. Siegfried and Autum Gaither-Davis
who established two of the lung carcinoma cell lines (201T
and 84T) from human lung carcinomas.
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Discussion
Dr Dao M. Nguyen (Bethesda, Md). Have you demon-
strated or do you have any idea whether Fas pathway is func-
tional in non–small cell lung cancer?
Dr Tracey L. Weigel. That is actually a very good ques-
tion. Around 1997, there were many reports suddenly that Fas
and FasL were on lung cancer cell lines, and most of these
studies were done by using immunostaining. Further work
has shown that actually this is probably a cytosolic expres-
sion of the Fas receptor, and many postulate now that there is
actually a defect in the exteriorization or the localization from
the cytosol to the surface of the Fas receptor, and that this, in
addition to the expression of FasL on the cell surface, may
actually be a way of immune escape by non–small cell lung
cancers. We were not able to demonstrate a role with respect
to Taxol for Fas receptor.
Dr Nguyen. Have you looked at Fas expression on the sur-
face by using FACS (fluorescence-activated cell sorter)?
Dr Weigel. Yes, we did. Actually, I did not have time to
present that, but we did not confirm what has been reported
by others with respect to the almost uniform expression of
Fas on the surface. We did see it on permeated cells (ie, in the
cytosol) but not on the cell surface.
Dr Nguyen. My previous work shows that about 30% to
40% of the lung cancer cell lines expressed variable degrees
of Fas, but whether the Fas pathway is functional is unclear.
The question of FasL expression on the surface of cells is still
a controversial issue at this point because FasL antibodies are
known to be unreliable in detecting FasL expression on the
surface of cells.
Dr Mark K. Ferguson (Chicago, Ill). I noticed that there
was some difference among the cell lines with regard to
paclitaxel-induced caspase-3 activity. Do you have some
explanation?
Dr Weigel. No, we do not. We did not see any consistent
difference. We used a variety of histologies in our cell
lines, but we did not see any consistent differences with
respect to histology. The cell line that really had no effect
was 84T, which was a primary tumor–derived culture, and
this may be because that cell line has been passaged quite
a bit. It is hard to say.
